MicroRNA-630: A potential guardian against inflammation in diabetic kidney disease

doi:10.4239/wjd.v15.i9.1837

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (735)

All Articles published online

The chart showing PDF series, WORD series, HTML series.

Item

Count

PDF

WORD

HTML

402

Sum=433

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

114

Sum=182

Publishing Process of This Article

Item

Count

Browse

Download

Sum=76

Sep 15, 2024 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Diabetes. Sep 15, 2024; 15(9): 1837-1841
Published online Sep 15, 2024. doi: 10.4239/wjd.v15.i9.1837

MicroRNA-630: A potential guardian against inflammation in diabetic kidney disease

Ashraf Al Madhoun

Ashraf Al Madhoun, Department of Genetics and Bioinformatics, Dasman Diabetes Institute, Dasman 15400, Kuwait

Author contributions: Al Madhoun A designed the overall concept, reviewed the literature, and wrote and edited the manuscript.

Supported by the Kuwait Foundation for the Advancement of Sciences and Dasman Diabetes Institute, Kuwait, No. RACB-2021-007.

Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Ashraf Al Madhoun, PhD, Academic Research, Senior Scientist, Department of Genetics and Bioinformatics, Dasman Diabetes Institute, Jassim AlBahar Street, Dasman 15400, Kuwait. ashraf.madhoun@dasmainstitute.org

Received: March 24, 2024
Revised: May 20, 2024
Accepted: June 17, 2024
Published online: September 15, 2024
Processing time: 156 Days and 1.4 Hours

Core Tip

Core Tip: Wu et al identified microRNA-630 as a promising candidate for the management of diabetic kidney disease, exerting its protective effects through the regulation of toll-like receptor 4-mediated inflammatory pathways. Further research elucidating the precise molecular mechanisms underlying microRNA-630’s actions and its therapeutic potential is warranted, with the ultimate goal of developing targeted interventions to alleviate the burden of diabetic kidney disease and improve patient outcomes.